Document:

Exhibit 4.1

 

 

 

HEALTHPEAK PROPERTIES, INC.

  

 

  

TENTH SUPPLEMENTAL INDENTURE

  

Dated as of June 23, 2020

  

to the

  

INDENTURE

  

Dated as of November 19, 2012

  

 

  

2.875% SENIOR NOTES DUE 2031

 

The Bank of New York Mellon Trust Company,
N.A.

  

Trustee

 

 

 

 

     

     

    

 

TABLE OF CONTENTS

 

	ARTICLE I DEFINITIONS	2
	Section 1.1	Definition of Terms	2
	 	 	 
	ARTICLE II GENERAL TERMS AND CONDITIONS OF THE NOTES	5
	Section 2.1	Designation and Principal Amount	5
	Section 2.2	Maturity	5
	Section 2.3	Further Issues	5
	Section 2.4	Form of Payment	5
	Section 2.5	Global Securities and Denomination of Notes	5
	Section 2.6	Interest	5
	Section 2.7	Redemption	6
	Section 2.8	Sinking Fund	6
	Section 2.9	Form of the Notes	6
	Section 2.10	Place of Payment	6
		 	 
	ARTICLE III ADDITIONAL COVENANTS APPLICABLE TO THE NOTES	6
	Section 3.1	Limitations on the Incurrence of Debt	6
	Section 3.2	Maintenance of Total Unencumbered Assets	7
	Section 3.3	Reports by the Company.	7
	Section 3.4	Additional Covenants.	8
	 	 	 
	ARTICLE IV EVENTS OF DEFAULT	9
	Section 4.1	Events of Default	9
	 	 	 
	ARTICLE V DEFEASANCE	9
	Section 5.1	Defeasance upon Deposit of Moneys or U.S. Government Obligations.	9
	 	 	 
	ARTICLE VI ORIGINAL ISSUANCE OF NOTES	9
	Section 6.1	Original Issue of Notes	9
	Section 6.2	Appointment of Agents. The Trustee shall initially be the Registrar and Paying Agent for the Notes.	9
	 	 	 
	ARTICLE VII MISCELLANEOUS	10
	Section 7.1	Applicability of Supplemental Indenture	10
	Section 7.2	Ratification of Indenture	10
	Section 7.3	Trustee Not Responsible for Recitals	10
	Section 7.4	Governing Law	10
	Section 7.5	Separability	10
	Section 7.6	Counterparts Originals	10

 

    i

     

    

 

TENTH SUPPLEMENTAL
INDENTURE, dated as of June 23, 2020 (this “Supplemental Indenture”), by and between HEALTHPEAK PROPERTIES, INC.
(formerly known as HCP, Inc.), a corporation duly organized and existing under the laws of the State of Maryland (the “Company”),
and The Bank of New York Mellon Trust Company, N.A., as trustee, a national banking association organized and existing under
the laws of the United States of America, as Trustee under the Indenture (as hereinafter defined) (the “Trustee”).

 

RECITALS OF THE COMPANY

 

A.       The
Company and the Trustee are parties to that certain Indenture, dated as of November 19, 2012 (the “Base Indenture”,
and as supplemented by this Supplemental Indenture, the “Indenture”), to provide for the issuance of Securities to
be issued in one or more series.

 

B.       Under
Section 14.01 of the Base Indenture, the Company and the Trustee are authorized to enter into one or more indentures supplemental
to the Base Indenture, without the consent of the Holders of Securities, in order to establish the forms and terms of Securities
of any series pursuant to Section 3.01 of the Base Indenture.

 

C.       The
Company desires to provide for the establishment of a new series of Securities under the Base Indenture to be known as the “2.875%
Senior Notes due 2031” (the “Notes”), the form and substance and the terms, provisions and conditions thereof
to be set forth as provided in the Base Indenture and this Supplemental Indenture.

 

D.       Concurrent
with the execution hereof, the Company has delivered to the Trustee an Officer’s Certificate and caused its counsel to deliver
to the Trustee an Opinion of Counsel, each pursuant to Section 16.01 of the Base Indenture.

 

E.       The
Company has done all things necessary to make this Supplemental Indenture a valid agreement of the Company, in accordance with
its terms.

 

NOW THEREFORE, in consideration
of the premises and the purchase and acceptance of the Notes by the Holders thereof, and for the purpose of setting forth, as provided
in the Base Indenture, the forms and terms of the Notes, the Company covenants and agrees, with the Trustee, as follows:

 

ARTICLE
I

 

DEFINITIONS

 

Section 1.1           
Definition of Terms. Unless the context otherwise requires:

 

(a)         
each term defined in the Base Indenture has the same meaning when used in this Supplemental Indenture;

 

(b)         
unless otherwise defined in the Indenture or the context otherwise requires, all terms used herein without definition which
are defined in the Trust Indenture Act, either directly or by reference therein, have the meanings assigned to them therein;

 

    

     

    

 

(c)         
the singular includes the plural and vice versa;

 

(d)         
headings are for convenience of reference only and do not affect interpretation;

 

(e)         
the words “herein”, “hereof” and “hereunder” and other words of similar import refer
to the Indenture as a whole and not to any particular Article, Section or other subdivision;

 

(f)          
a reference to a Section or Article is to a Section or Article of this Supplemental Indenture unless otherwise indicated;
and

 

(g)         
the following terms have the meanings given to them in this Section 1.1(g):

 

“Capitalized
Lease” means at any time any lease of Property which, in accordance with GAAP, would at such time be required to be capitalized
on a balance sheet of the lessee.

 

“Consolidated
EBITDA” means, for any period of time, the net income (loss) of the Company and its Subsidiaries, determined on a consolidated
basis in accordance with GAAP for such period, before deductions for (without duplication):

 

		(1)	Interest Expense;

 

		(2)	taxes;

 

		(3)	depreciation, amortization, and all other non-cash items, as determined reasonably and in good faith by the Company, deducted
in arriving at net income (loss);

 

		(4)	extraordinary items, including impairment charges;

 

		(5)	non-recurring items or other unusual items, as determined reasonably and in good faith by the Company (including, without limitation,
all prepayment penalties and all costs or fees incurred in connection with any debt financing or amendment thereto, acquisition,
disposition, recapitalization or similar transaction (regardless of whether such transaction is completed));

 

		(6)	noncontrolling interests;

 

		(7)	income or expense attributable to transactions involving derivative instruments that do not qualify for hedge accounting in
accordance with GAAP; and

 

		(8)	gains or losses on dispositions of depreciable real estate investments, property valuation losses and impairment charges.

 

    3

     

    

 

For purposes of calculating
Consolidated EBITDA, all amounts shall be as determined reasonably and in good faith by the Company, and in accordance with GAAP
except to the extent that GAAP is not applicable with respect to the determination of all non-cash and non-recurring items.

 

“Consolidated
Financial Statements” means, with respect to any Person, collectively, the consolidated financial statements and notes
to those financial statements, of that Person and its Subsidiaries prepared in accordance with GAAP.

 

“Incur”
means, with respect to any Debt or other obligation of any Person, to create, assume, guarantee or otherwise become liable in respect
of such Debt or other obligation, and “Incurrence” and “Incurred” have the meanings correlative to the
foregoing.

 

“Interest
Expense” means, for any period of time, the aggregate amount of interest recorded in accordance with GAAP for such period
by the Company and its Subsidiaries, but excluding (i) interest reserves funded from the proceeds of any loan, (ii) prepayment
penalties, (iii) amortization of deferred financing costs, and (iv) non-cash swap ineffectiveness charges, in all cases as reflected
in the applicable Consolidated Financial Statements.

 

“Latest Completed
Quarter” means, as of any date, the then most recently ended fiscal quarter of the Company for which Consolidated Financial
Statements of the Company have been completed, it being understood that at any time when the Company is subject to the informational
requirements of the Exchange Act, and in accordance therewith files annual and quarterly reports with the SEC, the term “Latest
Completed Quarter” shall be deemed to refer to the fiscal quarter covered by the Company’s most recently filed
Quarterly Report on Form 10-Q, or, in the case of the last fiscal quarter of the year, the Company’s Annual Report on Form
10-K.

 

“Property”
means any interest in any kind of property or asset, whether real, personal or mixed, tangible or intangible.

 

“Real Estate
Assets” means, as of any date, the real estate assets of such Person and its Subsidiaries on such date, on a consolidated
basis determined in accordance with GAAP.

 

“Secured Debt”
means, as of any date, that portion of the aggregate principal amount of all outstanding Debt of the Company and its Subsidiaries
as of that date that is secured by a Lien on properties or other assets of the Company or any of its Subsidiaries.

 

“Total Assets”
means, as of any date, the consolidated total assets of the Company and its Subsidiaries, as such amount would appear on a consolidated
balance sheet of the Company prepared as of such date in accordance with GAAP. “Total Assets” shall include Undepreciated
Real Estate Assets and all other assets but shall exclude goodwill, and shall include the proceeds of the Debt or Secured Debt
to be Incurred.

 

“Total Unencumbered
Assets” means, as of any date, Undepreciated Real Estate Assets of the Company and its Subsidiaries that are not subject
to any Lien which secures Debt of any of the Company and its Subsidiaries plus, without duplication, loan loss reserves relating
thereto, accumulated depreciation thereon, plus all other assets of the Company and its Subsidiaries as all such amounts would
appear on a consolidated balance sheet of the Company prepared as of such date in accordance with GAAP plus the proceeds of the
Debt or Secured Debt to be Incurred; provided, however, that “Total Unencumbered Assets” does not include net real
estate investments under unconsolidated joint ventures of the Company and its Subsidiaries and does not include goodwill.

 

    4

     

    

 

“Undepreciated
Real Estate Assets” means, as of any date, the amount of real estate assets valued at original cost plus capital improvements.

 

“Unsecured
Debt” means, as of any date, that portion of the aggregate principal amount of all outstanding Debt of the Company and
its Subsidiaries as of that date that is not Secured Debt.

 

ARTICLE
II

 

GENERAL TERMS AND CONDITIONS OF THE NOTES

 

Section 2.1           
Designation and Principal Amount. There is hereby authorized and established a new series of Securities under the
Base Indenture designated as the “2.875% Senior Notes due 2031,” which is not limited in aggregate principal amount.
The initial aggregate principal amount of the Notes to be issued on June 23, 2020 under this Supplemental Indenture shall be $600,000,000
(except for Notes authenticated and delivered upon transfer of, or in exchange for, or in lieu of, other Notes pursuant to Sections
3.04, 3.06, 3.07, 4.06 or 14.05 of the Base Indenture). Any additional amounts of Notes to be issued shall be set forth in an Officer’s
Certificate.

 

Section 2.2           
Maturity. The Stated Maturity of principal for the Notes shall be January 15, 2031.

 

Section 2.3           
Further Issues. The Company may from time to time, without the consent of the Holders of the Notes, issue additional
Notes, but only if such additional Notes are issued as part of a “qualified reopening” for U.S. federal income tax
purposes. Any such additional Notes shall have the same ranking, interest rate, maturity date and other terms as the outstanding
Notes (other than the offering price, the date of issuance and, under certain circumstances, the date from which interest thereon
shall begin to accrue and the first interest payment date). Any such additional Notes, together with the Notes herein provided
for, shall constitute a single series of Securities under the Indenture.

 

Section 2.4           
Form of Payment. The Notes shall be denominated in, and principal of, premium, if any, and interest on the Notes
shall be payable in U.S. dollars.

 

Section 2.5           
Global Securities and Denomination of Notes. Upon the original issuance, the Notes shall be represented by one or
more Global Securities without coupons. The Company shall issue the Notes in minimum denominations of $2,000 and in integral multiples
of $1,000 in excess thereof and shall deposit the Global Securities with the Trustee as custodian for DTC (which shall act as the
Depositary for the Notes) in New York, New York, and register the Global Securities in the name of DTC or its nominee.

 

Section 2.6           
Interest. The Notes shall bear interest (computed on the basis of a 360-day year consisting of twelve 30-day months)
from June 23, 2020 at the rate of 2.875% per annum payable in cash semiannually in arrears; interest payable on each Interest Payment
Date shall include interest accrued from June 23, 2020, or from the most recent Interest Payment Date to which interest has been
paid or duly provided for; the Interest Payment Dates on which such interest shall be payable are January 15 and July 15, commencing
on January 15, 2021; and interest shall be payable on any Interest Payment Date to the Person or Persons in whose name the Notes
are registered at the close of business on the fifteenth calendar day preceding the relevant Interest Payment Date.

 

    5

     

    

 

Section 2.7           
Redemption. The Notes are subject to redemption at the option of the Company as set forth in the form of Note attached
hereto as Exhibit A.

 

Section 2.8           
Sinking Fund. The Notes are not subject to any sinking fund.

 

Section 2.9            Form of the Notes. The Notes shall have such other terms and provisions as are set forth in the form of certificate
evidencing the Notes attached hereto as Exhibit A, all of which terms and provisions are incorporated by reference in and
made a part of Article II to this Supplemental Indenture as if set forth in full herein.

 

Section 2.10       
Place of Payment, Transfer and Exchange. Principal of, premium, if any, and interest on the Notes shall be payable,
Notes may be presented for registration of transfer or exchange, and notices and demands to or upon the Company in respect of the
Notes may be made, at the Corporate Trust Office of the Trustee.

 

ARTICLE
III

 

ADDITIONAL COVENANTS APPLICABLE TO THE NOTES

 

Section 3.1           
Limitations on the Incurrence of Debt.

 

(a)         
The Company shall not, and shall not permit any of its Subsidiaries to, Incur any Debt if, immediately after giving effect
to the Incurrence of such additional Debt and any other Debt Incurred since the end of the Latest Completed Quarter and the application
of the net proceeds therefrom, the aggregate principal amount of all outstanding Debt would exceed 60% of the sum of (without duplication)
(i) Total Assets as of the end of the Latest Completed Quarter and (ii) the purchase price of any Real Estate Assets or mortgages
receivable acquired or to be acquired in exchange for proceeds of any securities offering, and the amount of any securities offering
proceeds received (to the extent such proceeds were not used to acquire Real Estate Assets or mortgages receivable or to reduce
Debt), since the end of the Latest Completed Quarter.

 

(b)         
The Company shall not, and shall not permit any of its Subsidiaries to, Incur any Secured Debt if, immediately after giving
effect to the Incurrence of such additional Secured Debt and any other Secured Debt Incurred since the end of the Latest Completed
Quarter and the application of the net proceeds therefrom, the aggregate principal amount of all outstanding Secured Debt would
exceed 40% of the sum of (without duplication) (i) Total Assets as of the end of the Latest Completed Quarter and (ii) the purchase
price of any Real Estate Assets or mortgages receivable acquired or to be acquired in exchange for proceeds of any securities offering,
and the amount of any securities offering proceeds received (to the extent such proceeds were not used to acquire Real Estate Assets
or mortgages receivable or to reduce Debt), since the end of the Latest Completed Quarter.

 

    6

     

    

 

(c)         
The Company shall not, and shall not permit any of its Subsidiaries to, Incur any Debt if, immediately after giving effect
to the Incurrence of such additional Debt and any other Debt Incurred since the end of the Latest Completed Quarter and the application
of the net proceeds therefrom, the ratio of Consolidated EBITDA to Interest Expense for the four consecutive fiscal quarters ending
with the Latest Completed Quarter would be less than 1.50 to 1.00 on a pro forma basis and calculated on the assumption (without
duplication) that:

 

(i)       the
additional Debt and any other Debt Incurred by the Company or any of its Subsidiaries since the first day of such four-quarter
period to the date of determination, which was outstanding at the date of determination, had been Incurred at the beginning of
that period and continued to be outstanding throughout that period, and the application of the net proceeds of such Debt, including
to refinance other Debt, had occurred at the beginning of such period; provided that in determining the amount of Debt so Incurred,
the amount of Debt under any revolving credit facility shall be computed based upon the average daily balance of such Debt during
such period;

 

(ii)       the
repayment or retirement of any other Debt repaid or retired by the Company or any of its Subsidiaries since the first day of such
four-quarter period to the date of determination had occurred at the beginning of that period; provided that in determining the
amount of Debt so repaid or retired, the amount of Debt under any revolving credit facility shall be computed based upon the average
daily balance of such Debt during such period; and

 

(iii)       in
the case of any acquisition or disposition of any asset or group of assets (including, without limitation, by merger, or stock
or asset purchase or sale) or the placement of any assets in service or removal of any assets from service by the Company or any
of its Subsidiaries since the first day of such four-quarter period to the date of determination, the acquisition, disposition,
placement in service or removal from service and any related repayment or refinancing of Debt had occurred as of the first day
of such period, with the appropriate adjustments to Consolidated EBITDA and Interest Expense with respect to the acquisition, disposition,
placement in service or removal from service being included in that pro forma calculation.

 

Section 3.2          Maintenance
of Total Unencumbered Assets. The Company and its Subsidiaries shall maintain at all times Total Unencumbered Assets of
not less than 150% of the aggregate principal amount of all outstanding Unsecured Debt.

 

Section 3.3           
Reports by the Company.

 

For so long as the
Notes are outstanding, the Company shall:

 

(a)         
file with or deliver to the Trustee, within 15 days after the Company is required to file the same with the Securities
and Exchange Commission (the “SEC”), copies of the annual and quarterly reports and the information, documents and
other reports (or copies of such portions of any of the foregoing as the SEC may from time to time by rules and regulations prescribe)
that the Company may be required to file with the SEC pursuant to Section 13 or Section 15(d) of the Exchange Act; or,
if the Company is not required to file information, documents or reports with the SEC pursuant to either Section 13 or Section
15(d) of the Exchange Act, then the Company will file with or deliver to the Trustee and the SEC, in accordance with any other
rules and regulations that may be prescribed from time to time by the SEC, such annual and quarterly reports and supplementary
and periodic information, documents and reports that may be required pursuant to Section 13 of the Exchange Act, in respect
of a security listed and registered on a national securities exchange, as may be prescribed from time to time by the SEC in such
rules and regulations; or

 

    7

     

    

 

(b)         
if at any time the Company is not subject to Section 13 or 15(d) of the Exchange Act and the Company is not providing
annual and quarterly reports and supplementary and periodic information, documents and reports to the SEC and the Trustee pursuant
to Section 3.3(a) of this Supplemental Indenture, the Company will, at its option, either (i) post on a publicly available
website or (ii) post on IntraLinks or any comparable password protected online data system requiring user identification and
a confidentiality acknowledgement (a “Confidential Datasite”), within 15 days of the filing date that would be applicable
to a non-accelerated filer at that time pursuant to applicable SEC rules and regulations, the quarterly and audited annual financial
statements and accompanying disclosure described in Item 303 of Regulation S-K (“management’s discussion and analysis
of financial condition and results of operations”) that would be required to be contained in annual reports on Form 10-K
and quarterly reports on Form 10-Q, respectively, required to be filed with the SEC if the Company were subject to Section
13(a) or 15(d) of the Exchange Act. If the Company elects to furnish such reports via a Confidential Datasite, access to the Confidential
Datasite will be provided promptly upon request to Holders and beneficial owners of, and bona fide potential investors in, the
Notes as well as securities analysts and market makers and no such request for access to the Confidential Datasite will be unreasonably
denied.

 

Any such report, information
or document that the Company files with or furnishes to the SEC through the SEC’s Electronic Data Gathering Analysis and
Retrieval system (or any successor thereto) (“EDGAR”) shall be deemed filed with the Trustee for purposes of Section
3.3(a) and (b) of this Supplemental Indenture at the time of such filing or furnishing through EDGAR. Delivery of such reports,
information and documents to the Trustee is for informational purposes only, and the Trustee’s receipt of such will not constitute
actual or constructive notice of any information contained therein or determinable from information contained therein, including
the Company’s compliance with any of the Company’s covenants of the Indenture relating to the Notes (as to which the
Trustee is entitled to rely exclusively on an Officer’s Certificate).

 

Section 3.4           
Additional Covenants.

 

With respect to the
Notes, the covenants set forth in Sections 3.1 and 3.2 of this Supplemental Indenture supplement those covenants set forth in Article
VI of the Base Indenture and the covenant set forth in Section 3.3 of this Supplemental Indenture replaces in its entirety the
covenant set forth in Section 10.02 of the Base Indenture and with respect to the Notes, all references to Section 10.02 of the
Base Indenture contained in the Base Indenture and this Supplemental Indenture shall be deemed to refer to Section 3.3 of this
Supplemental Indenture.

 

    8

     

    

 

ARTICLE
IV

 

EVENTS OF DEFAULT

 

Section 4.1           
Events of Default.

 

The term “Event
of Default” as used in the Indenture with respect to the Notes shall include the following described event in addition to
those set forth in Section 7.01 of the Base Indenture:

 

(i)        if
any event of default as defined in any mortgage, indenture or instrument under which there may be issued, or by which there may
be secured or evidenced, any Debt (including obligations under Capitalized Leases) of the Company (including an Event of Default
with respect to any Outstanding Securities of any series other than the Notes) in an aggregate amount in excess of $50,000,000,
whether such Debt now exists or shall hereafter be created, shall happen and shall result in such Debt becoming or being declared
due and payable prior to the date on which it would otherwise become due and payable, and such acceleration shall not have been
rescinded or annulled within ten days after there shall have been given, by registered or certified mail, to the Company by the
Trustee or to the Company and the Trustee by the Holders of at least 25% in aggregate principal amount of the Outstanding Notes,
a written notice specifying such event of default and requiring the Company to cause such acceleration to be rescinded or annulled.

 

ARTICLE
V

 

DEFEASANCE

 

Section 5.1           
Defeasance upon Deposit of Moneys or U.S. Government Obligations.

 

At the Company’s
option, either (a) the Company shall be deemed to have been Discharged from its obligations with respect to the Notes on the first
day after the applicable conditions set forth in Section 12.03 of the Base Indenture have been satisfied or (b) the Company shall
cease to be under any obligation to comply with any term, provision or condition set forth in Section 6.08 or 10.02 of the Base
Indenture and Sections 3.1, 3.2 and 4.1 of this Supplemental Indenture with respect to the Notes at any time after the applicable
conditions set forth in Section 12.03 of the Base Indenture have been satisfied.

 

ARTICLE
VI

ORIGINAL ISSUANCE OF NOTES

 

Section 6.1           
Original Issue of Notes. The Notes may, upon execution of this Supplemental Indenture, be executed by the Company
and delivered to the Trustee for authentication, and the Trustee shall, upon receipt of a Company Order, authenticate and deliver
such series of Notes as in such Company Order provided.

 

Section 6.2           
Appointment of Agents. The Trustee shall initially be the Registrar and Paying Agent for the Notes.

 

    9

     

    

 

ARTICLE
VII

 

MISCELLANEOUS

 

Section 7.1           
Applicability of Supplemental Indenture. Each and every term and condition contained in this Supplemental Indenture
shall apply to the Notes issued on the date hereof or hereafter, but not to any other series of Securities issued or to be issued
under the Indenture. Except as specifically amended and supplemented by, or to the extent inconsistent with, this Supplemental
Indenture, the Indenture shall remain in full force and effect and is hereby ratified and confirmed.

 

Section 7.2           
Ratification of Indenture. The Base Indenture, as supplemented by this Supplemental Indenture, is in all respects
ratified and confirmed, and this Supplemental Indenture shall be deemed part of the Base Indenture in the manner and to the extent
herein and therein provided; provided that the provisions of this Supplemental Indenture apply solely with respect to these Notes.

 

Section 7.3           
Trustee Not Responsible for Recitals. The recitals herein contained are made by the Company and not by the Trustee,
and the Trustee assumes no responsibility for the correctness thereof. The Trustee makes no representation as to the validity or
sufficiency of this Supplemental Indenture.

 

Section 7.4           
Governing Law. This Supplemental Indenture and each Note shall be deemed to be contracts made under the law of the
State of New York, and for all purposes shall be governed by and construed in accordance with the law of said State.

 

Section 7.5           
Separability. In case any provision in this Supplemental Indenture or in any of the Notes of this series shall be
invalid, illegal or unenforceable, the validity, legality and enforceability of the remaining provisions shall not in any way be
affected or impaired thereby.

 

Section 7.6           
Counterparts Originals. This Supplemental Indenture may be executed in any number of counterparts, each of which
so executed shall be deemed to be an original, but all such counterparts shall together constitute but one and the same instrument.

 

    10

     

    

 

IN WITNESS WHEREOF,
the parties hereto have caused this Supplemental Indenture to be duly executed by their respective officers hereunto duly authorized,
all as of the day and year first above written.

 

	 	HEALTHPEAK PROPERTIES, INC.,
    as Issuer
	 	By: 	        /s/ Peter A. Scott
	 	Name:	Peter A. Scott
	 	Title:	Executive Vice President and Chief Financial Officer

 

[Signature Page to Supplemental Indenture]

 

    

     

    

 

	 	THE
    BANK OF NEW YORK MELLON
 TRUST COMPANY, N.A., as Trustee
	 	By:	         /s/ Kenneth Helbig
	 	Name:	Kenneth Helbig
	 	Title:	Vice President

 

[Signature Page to Supplemental Indenture]

 

    

     

    

 

EXHIBIT A

 

 

 

No. R-[●]

	
        CUSIP NO. 42250P AB9

        ISIN NO. US42250PAB94
	 	PRINCIPAL AMOUNT

 

$[ ]

 

HEALTHPEAK PROPERTIES, INC.

 

2.875% SENIOR NOTES DUE 2031

 

THIS SECURITY IS A
GLOBAL SECURITY WITHIN THE MEANING OF THE INDENTURE HEREINAFTER REFERRED TO AND IS REGISTERED IN THE NAME OF THE DEPOSITARY OR
A NOMINEE OF THE DEPOSITARY, WHICH SHALL BE TREATED BY THE COMPANY, THE TRUSTEE AND ANY AGENT THEREOF AS OWNER AND HOLDER OF THIS
SECURITY FOR ALL PURPOSES.

 

UNLESS THIS CERTIFICATE
IS PRESENTED BY AN AUTHORIZED REPRESENTATIVE OF THE DEPOSITORY TRUST COMPANY, A NEW YORK CORPORATION (“DTC”) TO THE
COMPANY OR ITS AGENT FOR REGISTRATION OF TRANSFER, EXCHANGE OR PAYMENT, AND ANY CERTIFICATE ISSUED IS REGISTERED IN THE NAME OF
CEDE & CO. OR IN SUCH OTHER NAME AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF DTC (AND ANY PAYMENT HEREON IS MADE TO
CEDE & CO. OR TO SUCH OTHER ENTITY AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF DTC), ANY TRANSFER, PLEDGE OR OTHER USE
HEREOF FOR VALUE OR OTHERWISE BY OR TO ANY PERSON IS WRONGFUL SINCE THE REGISTERED OWNER HEREOF, CEDE & CO., HAS AN INTEREST
HEREIN.

 

TRANSFERS OF THIS GLOBAL
SECURITY SHALL BE LIMITED TO TRANSFERS IN WHOLE, BUT NOT IN PART, BY THE DEPOSITARY TO A NOMINEE OF THE DEPOSITARY, OR BY A NOMINEE
OF THE DEPOSITARY TO THE DEPOSITARY OR ANOTHER NOMINEE OF THE DEPOSITARY, OR BY THE DEPOSITARY OR ANY SUCH NOMINEE TO A SUCCESSOR
DEPOSITARY OR A NOMINEE OF SUCH SUCCESSOR DEPOSITARY.

 

    

     

    

 

HEALTHPEAK PROPERTIES,
INC. (formerly known as HCP, Inc.), a Maryland corporation (the “Company”, which term shall include any successor under
the Indenture hereinafter referred to), for value received, hereby promises to pay to CEDE & CO., or registered assigns,
the principal sum of [ ] Million Dollars ($[ ]) on January 15, 2031, and to pay interest thereon from June 23, 2020 or from the
most recent interest payment date on which interest has been paid or duly provided for, semi-annually in arrears on January 15
and July 15 (each, an “Interest Payment Date”) of each year (or if such date is not a Business Day, on the next Business
Day thereafter; no interest will accrue on such payment for the period from and after such Interest Payment Date to the date of
such payment on the next succeeding Business Day), commencing January 15, 2021, at the rate of 2.875% per annum, until the entire
principal amount hereof is paid or duly provided for. The interest so payable, and punctually paid or duly provided for, on any
Interest Payment Date will, as provided in the Indenture, be paid to the Holder in whose name this Note (or one or more predecessor
Notes) is registered at the close of business on the Record Date for such interest, which shall be the date that is 15 calendar
days prior to such Interest Payment Date, whether or not a Business Day. Any such interest not so punctually paid or duly provided
for, on any Interest Payment Date shall forthwith cease to be payable to the Holder on such Record Date, and may either be
paid to the Holder in whose name this Note (or one or more predecessor Notes) is registered at the close of business on a Special
Record Date for the payment of such Defaulted Interest to be fixed by the Trustee, notice whereof shall be given to Holders of
Notes of this series not less than 10 calendar days prior to such Special Record Date, or may be paid at any time in
any other lawful manner not inconsistent with the requirements of any securities exchange on which the Notes may be listed,
and upon such notice as may be required by such exchange, all as more fully provided in the Indenture. Interest will be computed
on the basis of a 360-day year of twelve 30-day months. Payments of principal, premium, if any, and interest in respect of this
Note will be made by the Company in immediately available funds.

 

Payment of the principal
of and interest on this Note shall be payable at the Corporate Trust Office of The Bank of New York Mellon Trust Company, N.A.,
located at 101 Barclay Street, Floor 8 W, New York, New York 10286, or at such other office or agency of the Company maintained
for that purpose in The City of New York, in such coin or currency of the United States of America as at the time of payment is
legal tender for payment of public and private debts; provided, however, that, at the option of the Company, interest may be
paid by check mailed to the address of the Person entitled thereto as such address shall appear on the Register or by wire transfer
to an account designated by the Holder; and, provided, further, that so long as this Note is registered in the name of DTC or its
nominee, principal and interest payments will be paid to DTC or its nominee, as the Holder, by wire transfer in same-day funds.

 

Reference is hereby
made to the further provisions of this Note set forth on the reverse hereof, which further provisions shall for all purposes have
the same effect as if set forth at this place.

 

Unless the certificate
of authentication hereon has been executed by the Trustee by manual signature of one of its authorized signatories, this Note shall
not be entitled to any benefit under the Indenture or be valid or obligatory for any purpose.

 

    

     

    

 

IN WITNESS WHEREOF, the Company has caused
this instrument to be duly executed this 23rd day of June, 2020.

 

 

	 	Healthpeak Properties, Inc.,
	 	a Maryland corporation
	 	 	 
	 	By:	 
	 	Name:  	Peter A. Scott
	 	Title:	Executive Vice President and Chief Financial Officer

  

Attest:

  

	By:	 	 
	Name:  	Troy E. McHenry	 
	Title:	Executive Vice President, Chief Legal Officer and Corporate Secretary	 

 

    

     

    

 

TRUSTEE’S CERTIFICATE OF AUTHENTICATION:

 

This is one of the
Notes of the series designated herein referred to in the within-mentioned Indenture.

    

	 	The Bank of New York Mellon Trust Company, N.A., as Trustee
	 	 
	 	By:	 
	 	 	Authorized Signatory
	 	 
	 	Dated: June 23, 2020

 

    

     

    

 

This Note is one of
a duly authorized issue of securities designated as the “2.875% Senior Notes due 2031” (herein called the “Notes”)
of Healthpeak Properties, Inc. (formerly known as HCP, Inc.), a Maryland Corporation, and any of its successors and assigns (the
 “Company”), issued as a series of securities under an indenture, dated as of November 19, 2012 (the “Base
Indenture”), as supplemented by the Tenth Supplemental Indenture, dated as of June 23, 2020 (the “Supplemental Indenture”
and together with the Base Indenture, the “Indenture”), each between the Company and The Bank of New York Mellon Trust
Company, N.A. (the “Trustee,” which term includes any successor trustee under the Indenture with respect to the Notes).
Reference is hereby made for a statement of the respective rights, limitations of rights, duties and immunities thereunder of the
Company, the Trustee and the Holders of the Notes and of the terms upon which the Notes are, and are to be, authenticated and delivered.
This Note is one of a duly authorized series of securities of the Company originally limited (subject to exceptions provided
in the Indenture) in aggregate principal amount to $600,000,000; however, from time to time, without giving notice or seeking consent
of the Holders of the Notes, the Company may issue additional Notes of this series having the same ranking, interest rate
and maturity and other terms as this Note (other than the offering price, the date of issuance
and, under certain circumstances, the date from which interest thereon shall begin to accrue and the first interest payment date).
All terms used in this Note which are defined in the Indenture shall have the meanings assigned to them in the Indenture.

 

If an Event of Default
with respect to the Notes shall occur and be continuing, the principal of the Notes may be declared due and payable in the manner
and with the effect provided in the Indenture.

 

The Notes are not subject
to any sinking fund.

 

Prior
to the Par Call Date (as defined below), the Notes may be redeemed, at any time in whole or from time to time in part at the option
of the Company at a Redemption Price equal to the greater of: (1) 100% of the principal amount of the Notes to be redeemed on that
Redemption Date, or (2) the sum of the present values of the remaining scheduled payments of principal and interest on the
Notes to be redeemed (exclusive of interest accrued to, but excluding,
the Redemption Date) that would be due if the Notes matured on the Par Call Date, discounted
to the Redemption Date on a semi-annual basis (assuming a 360-day year consisting of twelve 30-day months) at the Treasury Rate
(as defined below) plus 35 basis points, plus, in either case,
accrued and unpaid interest on the Notes being redeemed to, but excluding, the Redemption Date; provided, however, that if the
Company redeems the Notes on and after the Par Call Date, the Company may at its option redeem the Notes at any time in whole or
from time to time in part at a Redemption Price that will equal 100% of the principal amount of the Notes to be redeemed plus accrued
and unpaid interest thereon to, but excluding, the Redemption Date; provided, further, that installments of interest on the Notes
that are due and payable on any Interest Payment Date falling on or prior to a Redemption Date for the Notes shall be payable on
such Interest Payment Dates to the Holder of the Note at the close of business on the applicable Record Dates. 

 

“Par Call Date” means
the date that is October 15, 2030.

 

“Treasury
Rate” means, the arithmetic mean (rounded to the nearest one-hundredth of one percent) of the yields displayed
for each of the five most recent days published in the most recent Statistical Release under the caption “Treasury constant
maturities” for the maturity (rounded to the nearest month) corresponding to the remaining life to maturity of the Notes
(assuming the Notes mature on the Par Call Date) as of the Redemption Date. If no maturity exactly corresponds to such remaining
life to maturity, yields for the two published maturities most closely corresponding to such remaining life to maturity shall be
calculated pursuant to the immediately preceding sentence and the Treasury Rate shall be interpolated or extrapolated from such
yields on a straight-line basis, rounding in each of such relevant periods to the nearest month. The Treasury Rate will be calculated
on the third Business Day preceding the date the applicable notice of redemption is given. For the purpose of calculating the Treasury
Rate, the most recent Statistical Release published prior to the date of calculation of the Treasury Rate shall be used.

 

    

     

    

 

“Statistical Release”
means that statistical release designated “H.15” or any successor publication published daily by the Board of Governors
of the Federal Reserve System and which establishes yields on actively traded U.S. Treasury securities adjusted to constant maturity,
or, if such release (or any successor publication) is no longer published at the time of any calculation under the Indenture, then
such other reasonably comparable index the Company designates.

 

The
Company may redeem the Notes in increments of $1,000 so long as, in the case of any Note redeemed in part, the unredeemed
principal amount thereof is $2,000 or an integral multiple of $1,000 in excess thereof.
If the Company redeems less than all of the Notes, the Notes to be redeemed will be selected in accordance with the procedures
of DTC. The Company will cause notices of redemption to be delivered at
least 15 but not more than 60 days before the Redemption Date to each Holder of Notes to be redeemed at its registered address
or by delivery to DTC for posting through its Legal Notice Service (“LENS”) or a successor system thereof. 

 

If this Note is to
be redeemed in part only, the notice of redemption that relates to this Note will state the portion of the principal amount thereof
to be redeemed. The Company will issue a Note in principal amount equal to the unredeemed portion of this Note in the name of the
Holder hereof upon cancellation of the original Note. Any Notes called for redemption will become due on the Redemption Date. On
or after the Redemption Date, interest will cease to accrue on the Notes or portions of them called for redemption. A
notice of redemption may be conditional.

 

As provided in and
subject to the provisions of the Indenture, the Holder of this Note shall not have any right to institute any action, suit or proceeding
at law or in equity for the execution of any trust under the Indenture or for the appointment of a receiver or for any other remedy
under the Indenture, in each case with respect to an Event of Default with respect to the Notes, unless such Holder previously
shall have given to the Trustee written notice of one or more of the Events of Default with respect to the Notes, and unless also
the Holders of 25% or more in principal amount of the Notes then Outstanding shall have requested the Trustee in writing to take
action in respect of the matter complained of, and unless also there shall have been offered to the Trustee security and indemnity
reasonably satisfactory to it against the costs, expenses and liabilities to be incurred therein or thereby, and the Trustee, for
60 days after receipt of such notification, request and offer of indemnity, shall have neglected or refused to institute any such
action, suit or proceeding; provided, however, that the foregoing shall not affect or impair the obligation of the Company, which
is absolute and unconditional, to pay the principal of, premium, if any, and interest on this Note to the Holder at the due date
herein stated, or affect or impair the right, which is also absolute and unconditional, of the Holder to institute suit to enforce
the payment thereof.

 

The Indenture permits,
with certain exceptions as therein provided, the amendment thereof and the modification of the rights and obligations of the Company
and the rights of the Holders of the Notes under the Indenture at any time by the Company and the Trustee with the consent of the
Holders of not less than a majority in aggregate principal amount of the Outstanding Notes. The Indenture also contains provisions
permitting the Holders of not less than a majority in principal amount of the Notes at the time Outstanding, on behalf of the Holders
of all Notes, to waive compliance by the Company with certain provisions of the Indenture. Furthermore, provisions in the Indenture
permit the Holders of not less than a majority of the aggregate principal amount of the Outstanding Notes to waive, in certain
circumstances, on behalf of all Holders of the Notes, certain past defaults under the Indenture and their consequences. Any such
consent or waiver by the Holder of this Note shall be conclusive and binding upon such Holder and upon all future Holders of this
Note and of any Note issued upon the registration of transfer hereof or in exchange herefor or in lieu hereof, whether or not notation
of such consent or waiver is made upon this Note.

 

No reference herein
to the Indenture and no provision of this Note or of the Indenture shall alter or impair the obligation of the Company, which is
absolute and unconditional, to pay the principal of, premium, if any and interest on, this Note at the times, places and rate,
and in the coin or currency, herein and in the Indenture prescribed.

 

    

     

    

 

As provided in the
Indenture and subject to certain limitations set forth therein, the transfer of this Note may be registered on the Register
upon surrender of this Note for registration of transfer at the office or agency of the Company maintained for the purpose in any
place where the principal of, premium, if any and interest on this Note are payable, duly endorsed by or accompanied by a written
instrument of transfer in form satisfactory to the Company, the Trustee and the Registrar duly executed by the Holder hereof
or by his attorney duly authorized in writing, and thereupon one or more new Notes of this series, of authorized denominations
and for the same aggregate principal amount, will be issued to the designated transferee or transferees.

 

This Note may be transferred,
in whole but not in part, only to a nominee of DTC, or by a nominee of DTC to DTC, or to a successor to DTC for such Global Security
selected or approved by the Company or to a nominee of such successor to DTC. If at any time DTC notifies the Company that it is
unwilling or unable to continue as Depositary for the Notes or if at any time DTC ceases to be a clearing agency registered under
the Exchange Act and any other applicable statute and regulation, if so required by applicable law or regulation, the Company shall
appoint a successor Depositary with respect to the Notes. If (a) a successor Depositary for the Notes is not appointed by the Company
within 90 days after the Company receives such notice or becomes aware of such ineligibility, as the case may be, (b) an Event
of Default has occurred and is continuing, or (c) the Company, in its sole discretion, determines at any time that all Notes (but
not less than all) of this series shall no longer be represented by such Global Note or Notes and executes and delivers to
the Trustee an Officer’s Certificate stating that the Notes shall be so exchangeable, then the Company shall execute, and
the Trustee shall authenticate and deliver, definitive Notes of like series, rank, tenor and terms in definitive form in an aggregate
principal amount equal to the principal amount of such Note or Notes.

 

The Notes are issuable
only in registered form without coupons and may be sold in denominations of $2,000 and integral multiples of $1,000 in excess
thereof. As provided in the Indenture and subject to certain limitations therein set forth, the Notes of this series are exchangeable
for a like aggregate principal amount of Notes of this series in authorized denominations as requested by the Holders surrendering
the same. No service charge shall be made for any such registration of transfer or exchange, but the Company or Trustee may in
certain circumstances require payment of a sum sufficient to cover any tax, assessment or other governmental charge payable in
connection therewith.

 

    

     

    

 

Prior to due presentment
of this Note for registration of transfer, the Company, the Trustee or any of their agents shall treat the Person in whose
name this Note is registered as the owner hereof for all purposes, whether or not this Note be overdue, and neither the Company,
the Trustee nor any of their agents shall be affected by notice to the contrary.

 

The Indenture contains
provisions whereby (i) the Indenture shall cease to be of further effect with respect to the Notes (subject to the survival of
certain provisions thereof), (ii) the Company may be discharged from its obligations with respect to the Notes (subject to certain
exceptions), or (iii) the Company may be released from its obligations under specified covenants and agreements in the Indenture,
in each case if the Company satisfies certain conditions provided in the Indenture.

 

No recourse shall be
had for the payment of the principal of, premium, if any, or interest on, this Note or for any claim based hereon or otherwise
in respect hereof or of the Debt represented hereby, or upon any obligation, covenant or agreement of the Indenture, against any
incorporator, stockholder, officer or director, as such, past, present or future, of the Company or of any successor corporation,
either directly or through the Company or any successor corporation, whether by virtue of any constitutional provision, statute
or rule of law, or by the enforcement of any assessment or penalty or otherwise; it being expressly agreed and understood that
the Indenture and this Note are solely corporate obligations, and that no personal liability whatsoever shall attach to, or be
incurred by, any incorporator, stockholder, officer or director, as such, past, present or future, of the Company or of any successor
corporation, either directly or through the Company or any successor corporation, because of the incurring of the Debt pursuant
to this Note or under or by reason of any of the obligations, covenants, promises or agreements contained in the Indenture or in
this Note, or to be implied herefrom, and that all liability, if any, of that character against every such incorporator, stockholder,
officer and director is, by the acceptance of this Note and as a condition of, and as part of the consideration for, the execution
of the Indenture and the issue of this Note expressly waived and released.

 

THE INDENTURE AND THE
NOTE SHALL BE DEEMED TO BE A CONTRACT MADE UNDER THE LAWS OF THE STATE OF NEW YORK, AND FOR ALL PURPOSES SHALL BE CONSTRUED IN
ACCORDANCE WITH THE LAWS OF SAID STATE.

 

Pursuant to a recommendation
promulgated by the Committee on Uniform Security Identification Procedures, the Company has caused CUSIP numbers to be printed
on the Notes as a convenience to the Holders of the Notes. No representation is made as to the correctness or accuracy of such
CUSIP numbers as printed on the Notes, and reliance may be placed only on the other identification numbers printed hereon.

 

All terms used in this
Note which are defined in the Indenture shall have the meanings assigned to them in the Indenture.

 

    

     

    

 

ASSIGNMENT FORM

FOR VALUE RECEIVED, THE UNDERSIGNED HEREBY

SELLS, ASSIGNS AND TRANSFERS TO

 

PLEASE INSERT SOCIAL

SECURITY OR OTHER IDENTIFYING

NUMBER OF ASSIGNEE

 

 

 

 

(Please Print or Typewrite Name and Address

including Zip Code of Assignee)

 

the within Note of                                         
 and                                   
        hereby does irrevocably constitute and appoint

 

 

Attorney to transfer said Note
on the books of the within-named Company with full power of substitution in the premises.

 

	Dated:	 	 	 	 
	 	 	 	 
	 	 	 	 	 	 

  

NOTICE: The signature to this assignment
must correspond with the name as it appears on the first page of the within Note in every particular, without alteration or
enlargement or any change whatever.Exhibit 4.2

 

THE REGISTERED HOLDER
OF THIS PURCHASE WARRANT BY ITS ACCEPTANCE HEREOF, AGREES THAT IT WILL NOT SELL, TRANSFER OR ASSIGN THIS PURCHASE WARRANT EXCEPT
AS HEREIN PROVIDED AND THE REGISTERED HOLDER OF THIS PURCHASE WARRANT AGREES THAT IT WILL NOT SELL, TRANSFER, ASSIGN, PLEDGE OR
HYPOTHECATE THIS PURCHASE WARRANT FOR A PERIOD OF ONE HUNDRED EIGHTY (180) DAYS FOLLOWING THE LATER OF THE EFFECTIVE DATE (DEFINED
BELOW) OR THE COMMENCEMENT OF SALES OF THE OFFERING TO WHICH THIS PURCHASE WARRANT RELATES TO ANYONE OTHER THAN (I) AEGIS CAPITAL
CORP. OR AN UNDERWRITER OR A SELECTED DEALER IN CONNECTION WITH THE OFFERING, OR (II) A BONA FIDE OFFICER OR PARTNER OF AEGIS CAPITAL
CORP. OR OF ANY SUCH UNDERWRITER OR SELECTED DEALER.

 

THIS PURCHASE WARRANT
IS NOT EXERCISABLE PRIOR TO [DATE THAT IS 180 DAYS FROM THE EFFECTIVE DATE OF THE OFFERING].

 

VOID AFTER 5:00 P.M.,
EASTERN TIME, [DATE THAT IS FIVE YEARS FROM THE EFFECTIVE DATE OF THE OFFERING]. 

 

WARRANT TO PURCHASE COMMON STOCK

 

GREENWICH LIFESCIENCES, INC.

 

Warrant Shares: ________________1

 

Initial Exercise Date: [DATE THAT IS
180 DAYS FROM THE EFFECTIVE DATE OF THE OFFERING]

 

THIS WARRANT TO PURCHASE
COMMON STOCK (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”)
is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on
or after _____________, 2021 (the “Initial Exercise Date”) and, in accordance with FINRA Rule 5110(f)(2)(G)(i),
prior to at 5:00 p.m. (New York time) on _____________, 2025 (the “Termination Date”), but not thereafter, to
subscribe for and purchase from Greenwich LifeSciences, Inc., a Delaware corporation (the “Company”), up to
_______________1 shares of common stock, par value $0.001 per share (the “Common Stock”), of the
Company (the “Warrant Shares”), as subject to adjustment hereunder. The purchase price of one Warrant Share
under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).

 

Section 1.Definitions.
In addition to the terms defined elsewhere in this Warrant, the following terms have the meanings indicated in this Section 1:

 

“Affiliate”
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common
control with a Person, as such terms are used in and construed under Rule 405 under the Securities Act.

 

“Business
Day” means any day except any Saturday, any Sunday, any day which is a federal legal holiday in the United States or
any day on which banking institutions in the State of New York are authorized or required by law or other governmental action to
close.

 

“Commission”
means the United States Securities and Exchange Commission.

 

“Effective
Date” means the effective date of the registration statement on Form S-1 (File No. 333-238829), including any related
prospectus or prospectuses, for the registration of the Company’s Common Stock and the Warrant Shares under the Securities
Act, that the Company has filed with the Commission.

 

 

 

 

		1	8% of the total number of shares sold in the offering,
excluding shares sold in connection with exercise of the over-allotment option.

     

     

    

 

“Exchange
Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.

 

“Person”
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability
company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.

 

“Rule 144”
means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted from time
to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect
as such Rule.

 

“Securities
Act” means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.

 

“Trading Day”
means a day on which the principal Trading Market located in the United States is open for trading.

 

“Trading Market”
means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date in question:
the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, or the New York Stock
Exchange (or any successors to any of the foregoing).

 

“Underwriting
Agreement” means the underwriting agreement, dated ________________, 2020, by and between the Company and Aegis Capital
Corp., as representatives of the underwriters set forth therein.

 

“VWAP”
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock then listed
or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding
date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading
Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the
volume weighted average price of a share of Common Stock for such date (or the nearest preceding date) on the OTCQB or OTCQX as
applicable, (c) if Common Stock is not then listed or quoted for trading on the OTCQB or OTCQX and if prices for Common Stock are
then reported in the “Pink Sheets” published by OTC Markets Group, Inc. (or a similar organization or agency succeeding
to its functions of reporting prices), the most recent bid price per share of Common Stock so reported, or (d) in all other cases,
the fair market value of the Common Stock as determined by an independent appraiser selected in good faith by the Holder and reasonably
acceptable to the Company, the fees and expenses of which shall be paid by the Company.

 

Section 2.Exercise.

 

a. Exercise
of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times on or after the Initial
Exercise Date and on or before the Termination Date by delivery to the Company (or such other office or agency of the Company as
it may designate by notice in writing to the registered Holder at the address of the Holder appearing on the books of the Company)
of a duly executed facsimile copy (or e-mail attachment) of the Notice of Exercise Form annexed hereto. Within two (2) Trading
Days following the date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise Price for the shares specified
in the applicable Notice of Exercise by wire transfer or cashier’s check drawn on a United States bank unless the cashless
exercise procedure specified in Section 2(c) below is specified in the applicable Notice of Exercise. No ink-original Notice of
Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise
form be required. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this
Warrant to the Company until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant has been exercised
in full, in which case, the Holder shall surrender this Warrant to the Company for cancellation within five (5) Trading Days of
the date the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant resulting in purchases of
a portion of the total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding number of
Warrant Shares purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Holder and the
Company shall maintain records showing the number of Warrant Shares purchased and the date of such purchases. The Company shall
deliver any objection to any Notice of Exercise Form within two (2) Business Days of receipt of such notice. The Holder and
any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following
the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder at any
given time may be less than the amount stated on the face hereof.

 

    1

     

    

 

b. Exercise
Price. The exercise price per share of the Common Stock under this Warrant shall be $_______2, subject
to adjustment hereunder (the “Exercise Price”). In the event that this Warrant is exercised for cash prior to
_______, 202__3, the Exercise Price shall be $______.4

 

c. Cashless
Exercise. If at any time on or after the Initial Exercise Date, there is no effective registration statement registering, or
the prospectus contained therein is not available for the issuance of the Warrant Shares to the Holder, then this Warrant may also
be exercised, in whole or in part, at such time by means of a “cashless exercise” in which the Holder shall be entitled
to receive the number of Warrant Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A), where:

 

(A) = as
applicable: (i) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise if such Notice
of Exercise is (1) both executed and delivered pursuant to Section 2(a) hereof on a day that is not a Trading Day or (2) both executed
and delivered pursuant to Section 2(a) hereof on a Trading Day prior to the opening of “regular trading hours” (as
defined in Rule 600(b)(64) of Regulation NMS promulgated under the federal securities laws) on such Trading Day, (ii) the VWAP
on the Trading Day immediately preceding the date of the applicable Notice of Exercise if such Notice of Exercise is executed during
“regular trading hours” on a Trading Day and is delivered within two (2) hours thereafter (including until two (2)
hours after the close of “regular trading hours” on a Trading Day) pursuant to Section 2(a) hereof or (iii) the VWAP
on the date of the applicable Notice of Exercise if the date of such Notice of Exercise is a Trading Day and such Notice of Exercise
is both executed and delivered pursuant to Section 2(a) hereof after the close of “regular trading hours” on such Trading
Day;

 

(B) = the
Exercise Price of this Warrant, as adjusted hereunder; and

 

(X) = the
number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if such
exercise were by means of a cash exercise rather than a cashless exercise.

 

If Warrant Shares are
issued in such a “cashless exercise,” the parties acknowledge and agree that in accordance with Section 3(a)(9) of
the Securities Act, the Warrant Shares shall take on the registered characteristics of the Warrants being exercised, and the holding
period of the Warrants being exercised may be tacked on to the holding period of the Warrant Shares. The Company agrees not to
take any position contrary to this Section 2(c).

 

 

 

		2	125% of the public offering price per share of common stock
in the offering.

		3	Date that is six months from the Initial Exercise Date.

		4	97% of 125% of the public offering price per share of common
stock in the offering.

    2

     

    

 

d. Mechanics
of Exercise.

 

i. Delivery
of Warrant Shares Upon Exercise. The Company shall cause the Warrant Shares purchased hereunder to be transmitted by its transfer
agent to the Holder by crediting the account of the Holder’s or its designee’s balance account with The Depository
Trust Company through DWAC if the Company is then a participant in such system and either (A) there is an effective registration
statement permitting the issuance of the Warrant Shares to or resale of the Warrant Shares by Holder, or (B) the Warrant Shares
are eligible for resale by the Holder without volume or manner-of-sale limitations pursuant to Rule 144 and, in either case, the
Warrant Shares have been sold by the Holder prior to the Warrant Share Delivery Date (as defined below), and otherwise by physical
delivery of a certificate, registered in the Company’s share register in the name of the Holder or its designee, for the
number of Warrant Shares to which the Holder is entitled pursuant to such exercise to the address specified by the Holder in the
Notice of Exercise by the date that is two (2) Trading Days after the delivery to the Company of the Notice of Exercise (such date,
the “Warrant Share Delivery Date”). If the Warrant Shares can be delivered via DWAC, the transfer agent shall
have received from the Company, at the expense of the Company, any legal opinions or other documentation required by it to deliver
such Warrant Shares without legend (subject to receipt by the Company of reasonable back up documentation from the Holder, including
with respect to affiliate status) and, if applicable and requested by the Company prior to the Warrant Share Delivery Date, the
transfer agent shall have received from the Holder a confirmation of sale of the Warrant Shares (provided the requirement of the
Holder to provide a confirmation as to the sale of Warrant Shares shall not be applicable to the issuance of unlegended Warrant
Shares upon a cashless exercise of this Warrant if the Warrant Shares are then eligible for resale pursuant to Rule 144(b)(1)).
The Warrant Shares shall be deemed to have been issued, and Holder or any other person so designated to be named therein shall
be deemed to have become a holder of record of such shares for all purposes, as of the date the Warrant has been exercised, with
payment to the Company of the Exercise Price (or by cashless exercise, if permitted) and all taxes required to be paid by the Holder,
if any, pursuant to Section 2(d)(vi) prior to the issuance of such shares, having been paid. If the Company fails for any reason
to deliver to the Holder the Warrant Shares subject to a Notice of Exercise by the second (2nd) Trading Day following
the Warrant Share Delivery Date, the Company shall pay to the Holder, in cash, as liquidated damages and not as a penalty, for
each $1,000 of Warrant Shares subject to such exercise (based on the VWAP of the Common Stock on the date of the applicable Notice
of Exercise), $10 per Trading Day (increasing to $20 per Trading Day on the fifth (5th) Trading Day after such liquidated
damages begin to accrue) for each Trading Day after the second Trading Day following such Warrant Share Delivery Date until such
Warrant Shares are delivered or Holder rescinds such exercise.

 

ii. Delivery
of New Warrants Upon Exercise. If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder
and upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant
evidencing the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall
in all other respects be identical with this Warrant.

 

iii. Rescission
Rights. If the Company fails to cause its transfer agent to deliver to the Holder the Warrant Shares pursuant to Section 2(d)(i)
by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise; provided, however,
that the Holder shall be required to return any Warrant Shares or Common Stock subject to any such rescinded exercise notice concurrently
with the return to Holder of the aggregate Exercise Price paid to the Company for such Warrant Shares and the restoration of Holder’s
right to acquire such Warrant Shares pursuant to this Warrant (including, issuance of a replacement warrant certificate evidencing
such restored right).

 

iv. Compensation
for Buy-In on Failure to Timely Deliver Warrant Shares upon Exercise. In addition to any other rights available to the Holder,
if the Company fails to cause its transfer agent to transmit to the Holder the Warrant Shares pursuant to an exercise on or before
the Warrant Share Delivery Date, and if after such date the Holder is required by its broker to purchase (in an open market transaction
or otherwise) or the Holder’s brokerage firm otherwise purchases, shares of Common Stock to deliver in satisfaction of a
sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise (a “Buy-In”),
then the Company shall (A) pay in cash to the Holder the amount, if any, by which (x) the Holder’s total purchase price (including
brokerage commissions, if any) for the shares of Common Stock so purchased exceeds (y) the amount obtained by multiplying (1) the
number of Warrant Shares that the Company was required to deliver to the Holder in connection with the exercise at issue times
(2) the price at which the sell order giving rise to such purchase obligation was executed, and (B) at the option of the Holder,
either reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise was not honored (in
which case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock that would have
been issued had the Company timely complied with its exercise and delivery obligations hereunder. For example, if the Holder purchases
Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of shares of Common
Stock with an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A) of the immediately preceding
sentence the Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating
the amounts payable to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss.
Nothing herein shall limit a Holder’s right to pursue any other remedies available to it hereunder, at law or in equity including,
without limitation, a decree of specific performance and/or injunctive relief with respect to the Company’s failure to timely
deliver shares of Common Stock upon exercise of the Warrant as required pursuant to the terms hereof.

 

    3

     

    

 

v. No
Fractional Shares or Scrip. No fractional shares or scrip representing fractional shares shall be issued upon the exercise
of this Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the
Company shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction
multiplied by the Exercise Price or round up to the next whole share.

 

vi. Charges,
Taxes and Expenses. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or
other incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the
Company, and such Warrant Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder;
provided, however, that in the event that Warrant Shares are to be issued in a name other than the name of the Holder,
this Warrant when surrendered for exercise shall be accompanied by the Assignment Form attached hereto duly executed by the Holder
and the Company may require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental
thereto. The Company shall pay all transfer agent fees required for same-day processing of any Notice of Exercise and all fees
to the Depository Trust Company (or another established clearing corporation performing similar functions) required for same-day
electronic delivery of the Warrant Shares.

 

vii. Closing
of Books. The Company will not close its stockholder books or records in any manner which prevents the timely exercise of this
Warrant, pursuant to the terms hereof.

 

viii. Signature.
This Section 2 and the exercise form attached hereto set forth the totality of the procedures required of the Holder in order to
exercise this Purchase Warrant. Without limiting the preceding sentences, no ink-original exercise form shall be required, nor
shall any medallion guarantee (or other type of guarantee or notarization) of any exercise form be required in order to exercise
this Purchase Warrant. No additional legal opinion, other information or instructions shall be required of the Holder to exercise
this Purchase Warrant. The Company shall honor exercises of this Purchase Warrant and shall deliver Shares underlying this Purchase
Warrant in accordance with the terms, conditions and time periods set forth herein.

 

e. Holder’s
Exercise Limitations. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the right to exercise
any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect to such issuance after
exercise as set forth on the applicable Notice of Exercise, the Holder (together with the Holder’s Affiliates, and any other
Persons acting as a group together with the Holder or any of the Holder’s Affiliates), would beneficially own in excess of
the Beneficial Ownership Limitation (as defined below). For purposes of the foregoing sentence, the number of shares of Common
Stock beneficially owned by the Holder and its Affiliates shall include the number of shares of Common Stock issuable upon exercise
of this Warrant with respect to which such determination is being made, but shall exclude the number of shares of Common Stock
which would be issuable upon (i) exercise of the remaining, nonexercised portion of this Warrant beneficially owned by the Holder
or any of its Affiliates and (ii) exercise or conversion of the unexercised or nonconverted portion of any other securities of
the Company (including, without limitation, any other Common Stock equivalents) subject to a limitation on conversion or exercise
analogous to the limitation contained herein beneficially owned by the Holder or any of its Affiliates. Except as set forth in
the preceding sentence, for purposes of this Section 2(e), beneficial ownership shall be calculated in accordance with Section
13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it being acknowledged by the Holder that the Company
is not representing to the Holder that such calculation is in compliance with Section 13(d) of the Exchange Act and the Holder
is solely responsible for any schedules required to be filed in accordance therewith. To the extent that the limitation contained
in this Section 2(e) applies, the determination of whether this Warrant is exercisable (in relation to other securities owned by
the Holder together with any Affiliates) and of which portion of this Warrant is exercisable shall be in the sole discretion of
the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder’s determination of whether this Warrant
is exercisable (in relation to other securities owned by the Holder together with any Affiliates) and of which portion of this
Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation, and the Company shall have no obligation to
verify or confirm the accuracy of such determination. In addition, a determination as to any group status as contemplated above
shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder.
For purposes of this Section 2(e), in determining the number of outstanding shares of Common Stock, a Holder may rely on the number
of outstanding shares of Common Stock as reflected in (A) the Company’s most recent periodic or annual report filed with
the Commission, as the case may be, (B) a more recent public announcement by the Company or (C) a more recent written notice by
the Company or the Company’s transfer agent setting forth the number of shares of Common Stock outstanding. Upon the written
or oral request of a Holder, the Company shall within two (2) Trading Days confirm orally and in writing to the Holder the number
of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common Stock shall be determined after
giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder or its Affiliates
since the date as of which such number of outstanding shares of Common Stock was reported. The “Beneficial Ownership Limitation”
shall be [4.99]% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares
of Common Stock issuable upon exercise of this Warrant. The Holder, upon notice to the Company, may increase or decrease the Beneficial
Ownership Limitation provisions of this Section 2(e), provided that the Beneficial Ownership Limitation in no event exceeds 9.99%
of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock
upon exercise of this Warrant held by the Holder and the provisions of this Section 2(e) shall continue to apply. Any increase
in the Beneficial Ownership Limitation will not be effective until the 61st day after such notice is delivered to the Company.
The provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity with the terms
of this Section 2(e) to correct this paragraph (or any portion hereof) which may be defective or inconsistent with the intended
Beneficial Ownership Limitation herein contained or to make changes or supplements necessary or desirable to properly give effect
to such limitation. The limitations contained in this paragraph shall apply to a successor holder of this Warrant.

 

    4

     

    

 

Section 3.Certain
Adjustments.

 

a. Stock
Dividends and Splits. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or otherwise
makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable
in shares of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon
exercise of this Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including
by way of reverse stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv) issues by reclassification
of shares of the Common Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied
by a fraction of which the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding
immediately before such event and of which the denominator shall be the number of shares of Common Stock outstanding immediately
after such event, and the number of shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the
aggregate Exercise Price of this Warrant shall remain unchanged. Any adjustment made pursuant to this Section 3(a) shall become
effective immediately after the record date for the determination of stockholders entitled to receive such dividend or distribution
and shall become effective immediately after the effective date in the case of a subdivision, combination or re-classification.
For the purposes of clarification, the Exercise Price of this Warrant will not be adjusted in the event that the Company or any
subsidiary thereof, as applicable, sells or grants any option to purchase, or sell or grant any right to reprice, or otherwise
dispose of or issue (or announce any offer, sale, grant or any option to purchase or other disposition) any Common Stock or Common
Stock equivalents, at an effective price per share less than the Exercise Price then in effect.

 

b.  [RESERVED]

 

c. Subsequent
Rights Offerings. In addition to any adjustments pursuant to Section 3(a) above, if at any time the Company grants, issues
or sells any Common Stock equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record
holders of any class of shares of Common Stock (the “Purchase Rights”), then the Holder will be entitled to
acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired
if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to
any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date
on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as
of which the record holders of shares of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights
(provided, however, to the extent that the Holder’s right to participate in any such Purchase Right would result in the Holder
exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Purchase Right to such
extent (or beneficial ownership of such shares of Common Stock as a result of such Purchase Right to such extent) and such Purchase
Right to such extent shall be held in abeyance for the Holder until such time, if ever, as its right thereto would not result in
the Holder exceeding the Beneficial Ownership Limitation).

 

    5

     

    

 

d. Pro Rata Distributions.
During such time as this Warrant is outstanding, if the Company shall declare or make any dividend (other than cash dividends)
or other distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of
capital or otherwise (including, without limitation, any distribution of shares or other securities, property or options by way
of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a “Distribution”),
at any time after the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution
to the same extent that the Holder would have participated therein if the Holder had held the number of shares of Common Stock
acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation,
the Beneficial Ownership Limitation) immediately before the date of which a record is taken for such Distribution, or, if no such
record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the participation in
such Distribution (provided, however, to the extent that the Holder’s right to participate in any such Distribution would
result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such
Distribution to such extent (or in the beneficial ownership of any shares of Common Stock as a result of such Distribution to such
extent) and the portion of such Distribution shall be held in abeyance for the benefit of the Holder until such time, if ever,
as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation). To the extent that this Warrant
has not been partially or completely exercised at the time of such Distribution, such portion of the Distribution shall be held
in abeyance for the benefit of the Holder until the Holder has exercised this Warrant.

 

e. Fundamental Transaction.
If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or more related transactions
effects any merger or consolidation of the Company with or into another Person, (ii) the Company, directly or indirectly, effects
any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of its assets in one
or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether by
the Company or another Person) is completed pursuant to which holders of Common Stock are permitted to sell, tender or exchange
their shares for other securities, cash or property and has been accepted by the holders of 50% or more of the outstanding Common
Stock, (iv) the Company, directly or indirectly, in one or more related transactions effects any reclassification, reorganization
or recapitalization of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted
into or exchanged for other securities, cash or property, or (v) the Company, directly or indirectly, in one or more related transactions
consummates a stock or share purchase agreement or other business combination (including, without limitation, a reorganization,
recapitalization, spin-off or scheme of arrangement) with another Person or group of Persons whereby such other Person or group
acquires more than 50% of the outstanding shares of Common Stock (not including any shares of Common Stock held by the other Person
or other Persons making or party to, or associated or affiliated with the other Persons making or party to, such stock or share
purchase agreement or other business combination) (each a “Fundamental Transaction”), then, upon any subsequent
exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would have been issuable upon
such exercise immediately prior to the occurrence of such Fundamental Transaction, at the option of the Holder (without regard
to any limitation in Section 2(e) on the exercise of this Warrant), the number of shares of Common Stock of the successor or acquiring
corporation or of the Company, if it is the surviving corporation, and any additional consideration (the “Alternate Consideration”)
receivable by holders of Common Stock as a result of such Fundamental Transaction for each share of Common Stock for which this
Warrant is exercisable immediately prior to such Fundamental Transaction (without regard to any limitation in Section 2(e) on the
exercise of this Warrant). For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted
to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common
Stock in such Fundamental Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration in
a reasonable manner reflecting the relative value of any different components of the Alternate Consideration. If holders of Common
Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the Holder
shall be given the same choice as to the Alternate Consideration it receives upon any exercise of this Warrant following such Fundamental
Transaction. The Company shall cause any successor entity in a Fundamental Transaction in which the Company is not the survivor
(the “Successor Entity”) to assume in writing all of the obligations of the Company under this Warrant in accordance
with the provisions of this Section 3(e) pursuant to written agreements in form and substance reasonably satisfactory to the Holder
and approved by the Holder (without unreasonable delay) prior to such Fundamental Transaction and shall, at the option of the Holder,
deliver to the Holder in exchange for this Warrant a security of the Successor Entity evidenced by a written instrument substantially
similar in form and substance to this Warrant which is exercisable for a corresponding number of shares of capital stock of such
Successor Entity (or its parent entity) equivalent to the shares of Common Stock acquirable and receivable upon exercise of this
Warrant (without regard to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and with an
exercise price which applies the Exercise Price hereunder to such shares of capital stock (but taking into account the relative
value of the shares of Common Stock pursuant to such Fundamental Transaction and the value of such shares of capital stock, such
number of shares of capital stock and such exercise price being for the purpose of protecting the economic value of this Warrant
immediately prior to the consummation of such Fundamental Transaction), and which is reasonably satisfactory in form and substance
to the Holder. Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall succeed to, and be substituted
for (so that from and after the date of such Fundamental Transaction, the provisions of this Warrant referring to the “Company”
shall refer instead to the Successor Entity), and may exercise every right and power of the Company and shall assume all of the
obligations of the Company under this Warrant with the same effect as if such Successor Entity had been named as the Company herein.

 

    6

     

    

 

f. Calculations.
All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be.
For purposes of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall
be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.

 

g. Notice
to Holder.

 

i. Adjustment
to Exercise Price. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company shall promptly
mail to the Holder a notice setting forth the Exercise Price after such adjustment and any resulting adjustment to the number of
Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.

 

ii. Notice
to Allow Exercise by Holder. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on the
Common Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the
Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares
of capital stock of any class or of any rights, (D) the approval of any stockholders of the Company shall be required in connection
with any reclassification of the Common Stock, any consolidation or merger to which the Company is a party, any sale or transfer
of all or substantially all of the assets of the Company, or any compulsory share exchange whereby the Common Stock is converted
into other securities, cash or property, or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation
or winding up of the affairs of the Company, then, in each case, the Company shall cause to be mailed a notice to the Holder at
its last address as it shall appear upon the Warrant Register of the Company, at least 20 calendar days prior to the applicable
record or effective date hereinafter specified, stating (x) the date on which a record is to be taken for the purpose of such dividend,
distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common
Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the
date on which such reclassification, consolidation, merger, sale, transfer or share exchange is expected to become effective or
close, and the date as of which it is expected that holders of the Common Stock of record shall be entitled to exchange their shares
of the Common Stock for securities, cash or other property deliverable upon such reclassification, consolidation, merger, sale,
transfer or share exchange; provided that the failure to provide such notice or any defect therein shall not affect the validity
of the corporate action required to be specified in such notice. To the extent that any notice provided hereunder constitutes,
or contains, material, non-public information regarding the Company or any of its subsidiaries, the Company shall simultaneously
file such notice with the Commission pursuant to a Current Report on Form 8-K. The Holder shall remain entitled to exercise this
Warrant during the period commencing on the date of such notice to the effective date of the event triggering such notice except
as may otherwise be expressly set forth herein.

 

    7

     

    

 

Section 4.Transfer
of Warrant.

 

a Transferability.
Pursuant to FINRA Rule 5110(g)(1), neither this Warrant nor any Warrant Shares issued upon exercise of this Warrant shall be sold,
transferred, assigned, pledged, or hypothecated, or be the subject of any hedging, short sale, derivative, put, or call transaction
that would result in the effective economic disposition of the securities by any person for a period of 180 days immediately following
the Effective Date or commencement of sales of the offering pursuant to which this Warrant is being issued, except the transfer
of any security:

 

i.by operation
of law or by reason of reorganization of the Company;

 

ii.to any FINRA
member firm participating in the offering and the officers or partners thereof, if all securities so transferred remain subject
to the lock-up restriction in this Section 4(a) for the remainder of the time period;

 

iii.if the
aggregate amount of securities of the Company held by the Holder or related person do not exceed one percent (1%) of the securities
being offered;

 

iv.that is
beneficially owned on a pro-rata basis by all equity owners of an investment fund, provided that no participating member manages
or otherwise directs investments by the fund, and participating members in the aggregate do not own more than ten percent (10%)
of the equity in the fund; or

 

v.the exercise
or conversion of any security, if all securities received remain subject to the lock-up restriction in this Section 4(a) for the
remainder of the time period.

 

Subject to the foregoing
restriction, any applicable securities laws and the conditions set forth in Section 4(d), this Warrant and all rights hereunder
(including, without limitation, any registration rights) are transferable, in whole or in part, upon surrender of this Warrant
at the principal office of the Company or its designated agent, together with a written assignment of this Warrant substantially
in the form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient to pay any transfer taxes
payable upon the making of such transfer. Upon such surrender and, if required, such payment, the Company shall execute and deliver
a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination or denominations specified
in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not so assigned,
and this Warrant shall promptly be cancelled. Notwithstanding anything herein to the contrary, the Holder shall not be required
to physically surrender this Warrant to the Company unless the Holder has assigned this Warrant in full, in which case, the Holder
shall surrender this Warrant to the Company within three (3) Trading Days of the date the Holder delivers an assignment form to
the Company assigning this Warrant full. The Warrant, if properly assigned in accordance herewith, may be exercised by a new holder
for the purchase of Warrant Shares without having a new Warrant issued.

 

b. New
Warrants. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of the
Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by
the Holder or its agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved in such
division or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants
to be divided or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the initial
issuance date of this Warrant and shall be identical with this Warrant except as to the number of Warrant Shares issuable pursuant
thereto.

 

c. Warrant
Register. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the “Warrant
Register”), in the name of the record Holder hereof from time to time. The Company may deem and treat the registered
Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and
for all other purposes, absent actual notice to the contrary.

 

    8

     

    

 

d. Representation
by the Holder. The Holder, by the acceptance hereof, represents and warrants that it is acquiring this Warrant and, upon any
exercise hereof, will acquire the Warrant Shares issuable upon such exercise, for its own account and not with a view to or for
distributing or reselling such Warrant Shares or any part thereof in violation of the Securities Act or any applicable state securities
law, except pursuant to sales registered or exempted under the Securities Act.

 

Section 5.Registration
Rights.

 

a. Demand
Registration.

 

i.Grant of Right.
The Company, upon written demand (a “Demand Notice”) of the Holder(s) of at least 51% of the Warrants and/or
the underlying Warrant Shares, agrees to register on Form S-3 (if available) or Form S-1 (if Form S-3 is not available), on one
occasion, all or any portion of the Warrant Shares underlying the Warrants (collectively, the “Registrable Securities”).
On such occasion, the Company will file a registration statement with the Commission covering the Registrable Securities within
sixty (60) days after receipt of a Demand Notice and use its reasonable best efforts to have the registration statement declared
effective promptly thereafter, subject to compliance with review by the Commission; provided, however, that the Company shall not
be required to comply with a Demand Notice if the Company has filed a registration statement with respect to which the Holder is
entitled to piggyback registration rights pursuant to Section 5(b) hereof and either: (i) the Holder has elected to participate
in the offering covered by such registration statement or (ii) if such registration statement relates to an underwritten primary
offering of securities of the Company, until the offering covered by such registration statement has been withdrawn or until thirty
(30) days after such offering is consummated. The demand for registration may be made at any time beginning on the Initial Exercise
Date. The Company covenants and agrees to give written notice of its receipt of any Demand Notice by any Holder(s) to all other
registered Holders of the Warrants and/or the Registrable Securities within ten (10) days after the date of the receipt of any
such Demand Notice.

 

ii. Terms.
The Company shall bear all fees and expenses attendant to the registration of the Registrable Securities pursuant to Section 5(a)(i),
but the Holders shall pay any and all underwriting commissions and the expenses of any legal counsel selected by the Holders to
represent them in connection with the sale of the Registrable Securities. The Company agrees to use its best efforts to cause the
filing required herein to become effective promptly and to qualify or register the Registrable Securities in such States as are
reasonably requested by the Holder(s); provided, however, that in no event shall the Company be required to register the Registrable
Securities in a State in which such registration would cause: (i) the Company to be obligated to register or license to do business
in such State or submit to general service of process in such State or (ii) the principal shareholders of the Company to be obligated
to escrow their shares of capital stock of the Company. The Company shall cause any registration statement filed pursuant to the
demand right granted under Section 5(a)(i) to remain effective for a period of at least twelve (12) consecutive months after the
date that the Holders of the Registrable Securities covered by such registration statement are first given the opportunity to sell
all of such securities. The Holders shall only use the prospectuses provided by the Company to sell the Warrant Shares covered
by such registration statement, and will immediately cease to use any prospectus furnished by the Company if the Company advises
the Holder that such prospectus may no longer be used due to a material misstatement or omission. Notwithstanding the provisions
of this Section 5(a)(ii), the Holder shall be entitled to a demand registration under this Section 5(a)(ii) on only one (1) occasion
and such demand registration right shall terminate on the fifth (5th) anniversary of the Effective Date or commencement
of sales of the offering pursuant to which this Warrant is being issued in accordance with FINRA Rule 5110(f)(2)(G)(iv).

 

b. “Piggy-Back”
Registration.

 

i. Grant
of Right. In addition to the demand right of registration described in Section 5(a) hereof, the Holder shall have the right,
for a period of no more than five years from the Effective Date in accordance with FINRA Rule 5110(f)(2)(G)(v), to include the
Registrable Securities as part of any other registration of securities filed by the Company (other than in connection with a transaction
contemplated by Rule 145(a) promulgated under the Securities Act or pursuant to Form S-8 or any equivalent form); provided, however,
that if, solely in connection with any primary underwritten public offering for the account of the Company, the managing underwriter(s)
thereof shall, in its reasonable discretion, impose a limitation on the number of shares of Common Stock which may be included
in the Registration Statement because, in such underwriter(s)’ judgment, marketing or other factors dictate such limitation
is necessary to facilitate public distribution, then the Company shall be obligated to include in such Registration Statement only
such limited portion of the Registrable Securities with respect to which the Holder requested inclusion hereunder as the underwriter
shall reasonably permit. Any exclusion of Registrable Securities shall be made pro rata among the Holders seeking to include Registrable
Securities in proportion to the number of Registrable Securities sought to be included by such Holders; provided, however, that
the Company shall not exclude any Registrable Securities unless the Company has first excluded all outstanding securities, the
holders of which are not entitled to inclusion of such securities in such Registration Statement or are not entitled to pro rata
inclusion with the Registrable Securities.

 

    9

     

    

 

ii. Terms.
The Company shall bear all fees and expenses attendant to registering the Registrable Securities pursuant to Section 5(b)(i) hereof,
but the Holders shall pay any and all underwriting commissions and the expenses of any legal counsel selected by the Holders to
represent them in connection with the sale of the Registrable Securities. In the event of such a proposed registration, the Company
shall furnish the then Holders of outstanding Registrable Securities with not less than fifteen (15) days written notice prior
to the proposed date of filing of such registration statement. Such notice to the Holders shall continue to be given for each registration
statement filed by the Company during the two (2) year period following the Initial Exercise Date until such time as all of the
Registrable Securities have been sold by the Holder. The holders of the Registrable Securities shall exercise the “piggy-back”
rights provided for herein by giving written notice within five (5) days of the receipt of the Company’s notice of its intention
to file a registration statement. Except as otherwise provided in this Warrant, there shall be no limit on the number of times
the Holder may request registration under this Section 5(b)(ii); provided, however, that such registration rights shall terminate
on the fifth (5th) anniversary of the date of the Underwriting Agreement in accordance with FINRA Rule 5110(f)(2)(G)(v).

 

c. General
Terms.

 

i. Indemnification.
The Company shall indemnify the Holder(s) of the Registrable Securities to be sold pursuant to any registration statement hereunder
and each person, if any, who controls such Holders within the meaning of Section 15 of the Securities Act or Section 20(a) of the
Exchange Act against all loss, claim, damage, expense or liability (including all reasonable attorneys’ fees and other expenses
reasonably incurred in investigating, preparing or defending against any claim whatsoever) to which any of them may become subject
under the Securities Act, the Exchange Act or otherwise, arising from such registration statement but only to the same extent and
with the same effect as the provisions pursuant to which the Company has agreed to indemnify the Underwriters contained in Section
7(a) of the Underwriting Agreement. The Holder(s) of the Registrable Securities to be sold pursuant to such registration statement,
and their successors and assigns, shall severally, and not jointly, indemnify the Company, against all loss, claim, damage, expense
or liability (including all reasonable attorneys’ fees and other expenses reasonably incurred in investigating, preparing
or defending against any claim whatsoever) to which they may become subject under the Securities Act, the Exchange Act or otherwise,
arising from information furnished by or on behalf of such Holders, or their successors or assigns, in writing, for specific inclusion
in such registration statement to the same extent and with the same effect as the provisions contained in Section 7(a) of the Underwriting
Agreement.

 

ii. Exercise
of Warrants. Nothing contained in this Warrant shall be construed as requiring the Holder(s) to exercise their Warrants prior
to or after the initial filing of any registration statement or the effectiveness thereof.

 

iii. Documents
Delivered to Holders. The Company shall deliver promptly to each Holder participating in the offering requesting the correspondence
and memoranda described below and to the managing underwriter, if any, copies of all correspondence between the Commission and
the Company, its counsel or auditors and all memoranda relating to discussions with the Commission or its staff with respect to
the registration statement and permit each Holder and underwriter to do such investigation, upon reasonable advance notice, with
respect to information contained in or omitted from the registration statement as it deems reasonably necessary to comply with
applicable securities laws or rules of FINRA. Such investigation shall include access to books, records and properties and opportunities
to discuss the business of the Company with its officers and independent auditors, all to such reasonable extent and at such reasonable
times as any such Holder shall reasonably request.

 

    10

     

    

 

iv.Intentionally
Omitted.

 

v. Documents
to be Delivered by Holder(s). Each of the Holder(s) participating in any of the foregoing offerings shall furnish to the Company
a completed and executed questionnaire provided by the Company requesting information customarily sought of selling security holders.

 

vi. Damages.
Should the registration or the effectiveness thereof required by Sections 5(a) or 5(b) hereof be delayed by the Company or the
Company otherwise fails to comply with such provisions, the Holder(s) shall, in addition to any other legal or other relief available
to the Holder(s), be entitled to obtain specific performance or other equitable (including injunctive) relief against the threatened
breach of such provisions or the continuation of any such breach, without the necessity of proving actual damages and without the
necessity of posting bond or other security.

 

Section 6.Miscellaneous.

 

a. No
Rights as Stockholder until Exercise. This Warrant does not entitle the Holder to any voting rights, dividends or other rights
as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i).

 

b. Loss,
Theft, Destruction or Mutilation of Warrant. The Company covenants that upon receipt by the Company of evidence reasonably
satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any certificate relating to the Warrant Shares,
and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant,
shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated,
the Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of
such Warrant or stock certificate.

 

c. Saturdays,
Sundays, Holidays, etc. If the last or appointed day for the taking of any action or the expiration of any right required or
granted herein shall not be a Trading Day, then, such action may be taken or such right may be exercised on the next succeeding
Trading Day.

 

d. Authorized
Shares. The Company covenants that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued
Common Stock a sufficient number of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase
rights under this Warrant. The Company further covenants that its issuance of this Warrant shall constitute full authority to its
officers who are charged with the duty of issuing the necessary Warrant Shares upon the exercise of the purchase rights under this
Warrant. The Company will take all such reasonable action as may be necessary to assure that such Warrant Shares may be issued
as provided herein without violation of any applicable law or regulation, or of any requirements of the Trading Market upon which
the Common Stock may be listed. The Company covenants that all Warrant Shares which may be issued upon the exercise of the purchase
rights represented by this Warrant will, upon exercise of the purchase rights represented by this Warrant and payment for such
Warrant Shares in accordance herewith, be duly authorized, validly issued, fully paid and nonassessable and free from all taxes,
liens and charges created by the Company in respect of the issue thereof (other than taxes in respect of any transfer occurring
contemporaneously with such issue).

 

Except and to the extent
as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its certificate
of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities
or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will
at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary
or appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality
of the foregoing, the Company will (i) not increase the par value of any Warrant Shares above the amount payable therefor upon
such exercise immediately prior to such increase in par value, (ii) take all such action as may be necessary or appropriate in
order that the Company may validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant
and (iii) use commercially reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory
body having jurisdiction thereof, as may be, necessary to enable the Company to perform its obligations under this Warrant.

 

    11

     

    

 

Before taking any action
which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the Exercise Price,
the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public
regulatory body or bodies having jurisdiction thereof.

 

e. Jurisdiction.
All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be determined in accordance
with the provisions of the Underwriting Agreement.

 

f. Restrictions.
The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, and the Holder does
not utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws.

 

g. Nonwaiver
and Expenses. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate
as a waiver of such right or otherwise prejudice the Holder’s rights, powers or remedies. Without limiting any other provision
of this Warrant or the Underwriting Agreement, if the Company willfully and knowingly fails to comply with any provision of this
Warrant, which results in any material damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient
to cover any costs and expenses including, but not limited to, reasonable attorneys’ fees, including those of appellate proceedings,
incurred by the Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies
hereunder.

 

h. Notices.
Any notice, request or other document required or permitted to be given or delivered to the Holder by the Company shall be delivered
in accordance with the notice provisions of the Underwriting Agreement.

 

i. Limitation
of Liability. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase
Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder
for the purchase price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company
or by creditors of the Company.

 

j. Remedies.
The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled
to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation
for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert
the defense in any action for specific performance that a remedy at law would be adequate.

 

k. Successors
and Assigns. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure
to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns
of Holder. The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and
shall be enforceable by the Holder or holder of Warrant Shares.

 

l. Amendment.
This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company and the Holder.

 

m. Severability.
Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable
law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective
to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions
of this Warrant.

 

n. Headings.
The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of
this Warrant.

 

********************

 

(Signature Page Follows)

 

    12

     

    

 

IN WITNESS WHEREOF,
the Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.

 

	 	GREENWICH LIFESCIENCES, INC.
	 	 	 
	 	By:	 
	 	 	Name:
	 	 	Title:

 

    13

     

    

 

NOTICE OF EXERCISE

 

TO: Greenwich
Life Sciences, Inc. 

 

(1) The
undersigned hereby elects to purchase _____________ Warrant Shares of the Company pursuant to the terms of the attached Warrant,
and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.

 

(2) Payment
shall take the form of (check applicable box):

 

		☐	in lawful money of the United States; or

 

		☐	if permitted the cancellation of such number of Warrant Shares as is necessary, in accordance with
the formula set forth in subsection 2(c), to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable
pursuant to the cashless exercise procedure set forth in subsection 2(c).

 

(3) Please
register and issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:

 

The Warrant Shares shall be delivered to
the following DWAC Account Number or by physical delivery of a certificate to:

 

[________________________]

[________________________]

[________________________]

 

(4) Accredited
Investor. If the Warrant is being exercised via cash exercise, the undersigned is an “accredited investor” as defined
in Regulation D promulgated under the Securities Act of 1933, as amended

 

[SIGNATURE OF HOLDER]

 

	Name of Investing Entity:	 
	 	 
	Signature of Authorized Signatory of Investing Entity:	 
	 	 
	Name of Authorized Signatory:	 
	 	 
	Title of Authorized Signatory:	 
	 	 
	Date:	 
	 	 	 	 

    14

     

    

 

ASSIGNMENT FORM

 

(To assign the foregoing warrant, execute

this form and supply required information.

Do not use this form to exercise the warrant.)

 

FOR VALUE RECEIVED, [     ] all of or [     ] shares
of the foregoing Warrant and all rights evidenced thereby are hereby assigned to

 

whose address is

 

.

 

Dated:             ,

 

Holder’s Signature:                   

 

Holder’s Address:                      

 

 

NOTE: The signature to this Assignment Form must correspond
with the name as it appears on the face of the Warrant, without alteration or enlargement or any change whatsoever. Officers of
corporations and those acting in a fiduciary or other representative capacity should file proper evidence of authority to assign
the foregoing Warrant.

 

 

15

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00310-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00310-of-00352.parquet"}]]